钙蛋白酶
医学
粪便细菌疗法
艰难梭菌
内科学
粪便
胃肠病学
临床意义
抗生素
微生物学
炎症性肠病
疾病
生物
作者
Antonella Gallo,Cristina Cancelli,Emily Ceron,Marcello Covino,Ettore Capoluongo,Krizia Pocino,Gianluca Ianiro,Giovanni Cammarota,Antonio Gasbarrini,Massimo Montalto
摘要
Abstract Background and Aim Fecal microbiota transplantation (FMT) has proven to be very effective in recurrent Clostridium difficile infection (CDI) when compared with standard antibiotic therapy. However, given the lack of validated criteria, decision regarding number and timing of infusions is currently based on the clinician's experience, severity of infection, and clinical response. We performed a longitudinal assessment of fecal calprotectin concentration (FCC) in CDI patients undergoing FMT. FCCs were correlated with the need for multiple infusions and with the clinical status of the patient. Methods Fecal calprotectin concentration measurement was performed just before first procedure ( T 0 ) and 2 ( T 1 ) and 5 ( T 2 ) days later. The need for reinfusion was accounted for in the 8 weeks following procedure, and clinical status was evaluated at the end of the given period. Both outcomes were correlated with measured FCCs. Results A total of 28 CDI patients undergoing FMT were enrolled. Median FCCs at T 0 were significantly higher in patients who needed repeat FMT, 540 μg/g versus patients who underwent single FMT, 290 μg/g ( P < 0.05). Differences were not significant for FCC at T 1 and T 2 . Regarding correlation with clinical outcome, median FCC at T 0 was found to be lower in responders compared with non‐responders with a trend towards statistical significance ( P = 0.07). Correlation at T 1 and T 2 was not significant. Conclusions The use of an easily obtainable parameter such as fecal calprotectin could possibly optimize overall management of FMT procedural framework potentially being able to immediately identify patients who may benefit from repeat infusions.
科研通智能强力驱动
Strongly Powered by AbleSci AI